Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
-
- Samantha C. Gouw
- Department of Paediatrics, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands;
-
- H. Marijke van den Berg
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands;
-
- Kathelijn Fischer
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands;
-
- Günter Auerswald
- Gesundheit Nord, Klinikum Bremen Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany;
-
- Manuel Carcao
- Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Canada;
-
- Elizabeth Chalmers
- Department of Haematology, Royal Hospital for Sick Children, Yorkhill, Glasgow, UK;
-
- Hervé Chambost
- Service d’hématologie pédiatrique, Hôpital La Timone & Aix-Marseille Univ, Marseille, France;
-
- Karin Kurnik
- Dr. v. Haunersches Kinderspital, University of Munich, Munich, Germany;
-
- Ri Liesner
- Hemophilia Center, Department of Haematology, Great Ormond Street Hospital for children, London, UK;
-
- Pia Petrini
- Department of Pediatrics, Clinic of Coagulation Disorders, Karolinska Hospital, Stockholm, Sweden;
-
- Helen Platokouki
- St. Sophia Children’s Hospital, Haemophilia-Haemostasis Unit, Athens, Greece;
-
- Carmen Altisent
- Unitat Hemofilia, Hospital Traumatologica, Hospital Vall d’Hebron, Barcelona, Spain;
-
- Johannes Oldenburg
- Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn, Bonn, Germany;
-
- Beatrice Nolan
- Department of Paediatric Haematology, St. James's Hospital, Dublin, Ireland;
-
- Rosario Pérez Garrido
- Hospital General Unidad de Hemofilia, Hospitales Universitarios Virgen del Rocio, Sevilla, Spain;
-
- M. Elisa Mancuso
- Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy;
-
- Anne Rafowicz
- Centre Régional de Traitement de l'Hémophilie et Autres Maladies Bicetre, Service Hématologique, Paris, France;
-
- Mike Williams
- Department of Haematology, The Children’s Hospital, Birmingham, UK;
-
- Niels Clausen
- Department of Pediatrics, University Hospital of Aarhus at Skejby, Aarhus, Denmark;
-
- Rutger A. Middelburg
- Center for Clinical Transfusion Research, Sanquin Foundation, Leiden, The Netherlands;
-
- Rolf Ljung
- Department of Pediatrics and Malmö Centre for Thrombosis and Haemostasis, Skånes Universitetssjukhus, Malmö, Sweden; and
-
- Johanna G. van der Bom
- Center for Clinical Transfusion Research, Sanquin Foundation, Leiden, The Netherlands;
書誌事項
- 公開日
- 2013-05-16
- DOI
-
- 10.1182/blood-2012-09-457036
- 公開者
- American Society of Hematology
この論文をさがす
説明
<jats:title>Key Points</jats:title> <jats:p>High-dose intensive factor VIII treatment increases the risk for inhibitor development in patients with severe hemophilia A. In patients with severe hemophilia A, factor VIII prophylaxis decreases inhibitor risk, especially in patients with low-risk F8 mutations.</jats:p>
収録刊行物
-
- Blood
-
Blood 121 (20), 4046-4055, 2013-05-16
American Society of Hematology